Effect of Corynoline Isolated from Corydalis bungeana Turcz on Lipopolysaccharides-Induced Sepsis In vivo and In vitro
Abstract
Purpose: To investigate the protective effect of corynoline isolated from Corydalis bungeana Turcz on lipopolysaccharides (LPS)-induced sepsis, and determine the possible mechanism of anti-sepsis effect of the isolated corynoline.
Methods: Corynoline was extracted by column chromatography. LPS (100 ng/mL) was used to induce the release of TNF-α and IL-6 in RAW 264.7 cells, and the isolated corynoline was added. ELISA method was used to determine the levels of TNF-α and IL- 6. Furthermore, sepsis in mice was established by injection of LPS (2 mg/kg, i.v.), and the levels of TNF- α and IL-6 in plasma were determined by ELISA method. For survival rate test, LPS (15 mg/kg, i.v.) and heat-killed E. coli (1.0 ~1011 CFU/kg, i.v.) were used to establish sepsis in mice model, and the mice were observed in 7 days.
Results: The results indicate that corynoline significantly elevated the survival rate of septic mice induced by LPS and heat-killed E. coli, in a dose-dependent manner (p < 0.05). Corynoline decreased the release of TNF-α and IL-6 induced by LPS, in a dose-dependent manner (p < 0.05).
Conclusion: Treatment with corynoline significantly inhibits the mortality of LPS-induced septic mice, and the mechanism of action is probably related to the decrease of TNF-α and IL-6 release. Thus corynoline has the potential to be developed as an effective and safe drug for treating sepsis.
Keywords: Corynoline, Corydalis bungeana, Sepsis, Lipopolysaccharides, TNF-α, IL-6
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
